CDXS — Codexis, Inc.

Summary of Codexis, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $70.4 million for 2025, up from $59.3 million in 2024, primarily driven by a $37.8 million technology transfer agreement with Merck.
• Product Gross Margin: Maintained at 64% for both Q4 and the full year, an improvement from 56% in 2024.
• Net Income: Reported at $9.6 million for 2025, a turnaround from a loss of $10.4 million in 2024. The net loss for the year was $44.0 million, reduced from $65.3 million in 2024.
• Cash Position: Ended 2025 with $78.2 million in cash and equivalents, expected to fund operations through 2027.

2. Strategic Updates and Business Highlights

• ECOsynthesis Platform: Codexis is focusing on RNA medicine with its ECOsynthesis platform, which aims to improve siRNA production. The company synthesized 10 grams of commercially relevant siRNA and is scaling up production to half a kilo by year-end 2026.
• Partnerships: Successfully signed three CDMO agreements with Bachem, Nitto Avecia, and Axolabs, indicating strong interest in their technology.
• Innovation: Introduced stereochemical control in siRNA synthesis, which could enhance drug potency and purity.
• Operational Improvements: Modernized non-GMP production capabilities and achieved ISO 9001 certification, enhancing customer confidence.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $72 million and $76 million, with a heavier revenue weighting anticipated in the second half of the year.
• Growth Strategy: Focus on expanding the ECOsynthesis technology and securing long-term contracts with higher dollar values. The company aims to demonstrate the value of their technology through successful customer engagements.

4. Bad News, Challenges, or Points of Concern

• Operational Costs: The company undertook a restructuring that included a one-time charge of $3.4 million, indicating potential challenges in managing operational expenses.
• Market Competition: The growing demand for siRNA production may lead to increased competition, and Codexis must prove its technology's superiority to capture market share.
• Dependency on Partnerships: Future revenue growth heavily relies on the successful adoption of the ECOsynthesis platform by partners, which carries inherent risks.

5. Notable Q&A Insights

• Stereoisomer Control: There is ongoing work to validate the biological activity of stereoisomer configurations, with expectations for data presentation at upcoming industry meetings.
• Contractual Pipeline: The recent low seven-figure contract for preclinical work is seen as a prototype for future agreements, with potential for significant revenue growth as products move into clinical trials.
• Visibility into Revenue Guidance: Management indicated a solid base for revenue projections based on historical customer buying practices, though some elements remain speculative.

Overall, Codexis is positioned for growth with its innovative ECOsynthesis platform and a solid financial foundation, but it faces challenges in operational management and market competition. The focus for 2026 will be on demonstrating the technology's value and expanding its commercial footprint.